CN108026577B - Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 - Google Patents

Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 Download PDF

Info

Publication number
CN108026577B
CN108026577B CN201680052340.6A CN201680052340A CN108026577B CN 108026577 B CN108026577 B CN 108026577B CN 201680052340 A CN201680052340 A CN 201680052340A CN 108026577 B CN108026577 B CN 108026577B
Authority
CN
China
Prior art keywords
cells
methylation
cell
cpg
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680052340.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108026577A (zh
Inventor
斯文·欧莱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Medical Co ltd
Original Assignee
Precision Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Medical Co ltd filed Critical Precision Medical Co ltd
Publication of CN108026577A publication Critical patent/CN108026577A/zh
Application granted granted Critical
Publication of CN108026577B publication Critical patent/CN108026577B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680052340.6A 2015-09-25 2016-09-22 Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 Active CN108026577B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1516971.7A GB201516971D0 (en) 2015-09-25 2015-09-25 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
GB1516971.7 2015-09-25
PCT/EP2016/072522 WO2017050882A1 (en) 2015-09-25 2016-09-22 Mvd as epigenetic marker for the identification of immune cells, in particular cd56+ nk cells

Publications (2)

Publication Number Publication Date
CN108026577A CN108026577A (zh) 2018-05-11
CN108026577B true CN108026577B (zh) 2022-09-23

Family

ID=54544101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680052340.6A Active CN108026577B (zh) 2015-09-25 2016-09-22 Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物

Country Status (8)

Country Link
US (1) US11788141B2 (https=)
EP (1) EP3353321B1 (https=)
JP (1) JP2018534910A (https=)
CN (1) CN108026577B (https=)
CA (1) CA2995350A1 (https=)
GB (1) GB201516971D0 (https=)
HK (1) HK1257705A1 (https=)
WO (1) WO2017050882A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017125013B4 (de) * 2017-10-25 2019-10-17 Epiontis Gmbh MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten
DE102018112644B4 (de) 2018-05-25 2020-06-10 Epiontis Gmbh CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen
DE102018116353B4 (de) * 2018-07-05 2020-06-10 Epiontis Gmbh Verfahren zum Nachweis und zur Zählung epigenetischer Immunzellen in humanen Blutproben für Immundiagnostik und Neugeborenen-Screening
CN119372341B (zh) * 2024-12-30 2025-04-11 北京致谱医学检验实验室有限公司 基于基因甲基化检测实现人nk淋巴细胞计数的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102343086A (zh) * 2010-05-28 2012-02-08 四川大学 治疗或预防肿瘤的药物、肿瘤全细胞疫苗及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH2220H1 (en) * 2001-08-10 2008-07-01 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
ES2367012T3 (es) * 2006-02-28 2011-10-27 Charite-Universitätsmedizin Berlin Detección y control de calidad de linfocitos t reguladores a través del análisis de metilación del adn del gen foxp3.
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
PL2248913T3 (pl) * 2009-04-28 2017-04-28 Epiontis Gmbh GNLY jako marker epigenetyczny do identyfikacji komórek naturalnej cytotoksyczności ekspresjonujących CD56
WO2012045888A1 (en) * 2010-10-08 2012-04-12 Epiontis Gmbh Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
GB201112586D0 (en) * 2011-07-22 2011-09-07 Epiontis Gmbh Epigenetic marker for the identification of natural killer cells
WO2013033627A2 (en) * 2011-09-01 2013-03-07 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102343086A (zh) * 2010-05-28 2012-02-08 四川大学 治疗或预防肿瘤的药物、肿瘤全细胞疫苗及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Genomic variations of the mevalonate pathway in porokeratosis;Zhenghua Zhang等;《Elife》;20150723;第4卷;第1-6页 *
NK cells gain higher IFN-γ competence during terminal differentiation;Merlin Luetke-Eversloh等;《Eur J Immunol》;20140731;第44卷(第7期);第2074-2084页 *
NK细胞调节移植物抗宿主病中同种反应性T细胞应答的作用及机制研究;盛立霞;《中国博士学位论文全文数据库医药卫生科技辑》;20150415(第4期);E060-14 *

Also Published As

Publication number Publication date
HK1257705A1 (zh) 2019-10-25
EP3353321A1 (en) 2018-08-01
CA2995350A1 (en) 2017-03-30
GB201516971D0 (en) 2015-11-11
JP2018534910A (ja) 2018-11-29
US20180237855A1 (en) 2018-08-23
US11788141B2 (en) 2023-10-17
EP3353321B1 (en) 2020-11-04
WO2017050882A1 (en) 2017-03-30
CN108026577A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
EP3353318B1 (en) Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells
CN108026590B (zh) Park2作为用于鉴定免疫细胞特别是单核细胞的表观遗传标志物
CN108026577B (zh) Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物
EP3227458B1 (en) Epigenetic method for the identification of follicular t-helper-(tfh-) cells
JP2021501574A (ja) 免疫細胞、特に好塩基性顆粒球の同定のためのエピジェネティックマーカーとしてのｍｃｃ
EP3669001B1 (en) Amplicon region as epigenetic marker for the identification of non-classical monocytes
EP3669003B1 (en) Pdcd1 as epigenetic marker for the identification of immune cells, in particular pd1+ cells
CA3082261C (en) Ergic1 as epigenetic marker for the identification of immune cells, in particular monocytic myeloid-derived suppressor cells (mmdscs)
CA3080060C (en) Pdcd1 as epigenetic marker for the identification of immune cells, in particular pd1+ cells
CA2999611C (en) Lrp5 as epigenetic marker for the identification of immune cells, in particular b-cells
WO2024245833A1 (en) Lag3 as epigenetic marker for the identification of immune cells
US20200347453A1 (en) ERGIC1 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR MONOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS (mMDSCs)
WO2021191369A1 (en) Cbx6 as epigenetic marker for the identification of immune cells, in particular memory b cells
HK1257582B (en) Park2 as epigenetic marker for the identification of immune cells, in particular monocytes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Berlin, Germany

Applicant after: Precision medical Co.,Ltd.

Address before: Berlin, Germany

Applicant before: EPIONTIS GmbH

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant